Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WIBDT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Pamlectabart tismanitin
|
|||||
| Synonyms |
pamlectabart tismanitin; HDP-101; HDM2027
Click to Show/Hide
|
|||||
| Organization |
Heidelberg Pharma (Originator);Huadong Medicine
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Pamlectabart
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
HDP 30.2115
|
Payload Info | ||||
| Therapeutic Target |
RNA polymerase II
|
Target Info | ||||
| Linker Name |
Mal-Val-Ala-PAB
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
tismanitin
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma |
1 Trials
|
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility requires adults (≥18) with IMWG-defined active MM after ≥3 prior lines (IMiD/PI/anti-CD38) who are transplant-ineligible/post-SCT, excluding those with plasma cell leukemia, active CNS/other malignancies, uncontrolled infections (HIV/HBV/HCV), or recent SCT/radiotherapy (<12/<21 weeks). Phase 2a specifically excludes prior BCMA-targeted therapy exposure.
Click to Show/Hide
|
||||
| Administration Dosage |
Participants will receive HDP-101 intravenously in a 21 day cycle until disease progression, intolerable toxicity, Investigator's discretion or patient withdrawal.During the phase 1 tolerability of different dose levels will be evaluated. During the phase 2a dose expansion part the recommended phase 2 dose (RP2D) of HDP-101 will be administered.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04879043 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma | ||||
| Primary Endpoint |
Primary endpoints evaluate safety (dose-limiting toxicities during first 21-day cycle) and efficacy (objective response rate per IMWG criteria including sCR/CR/VGPR/PR) in relapsed/refractory multiple myeloma patients over approximately 1 year.
|
||||
| Other Endpoint |
Secondary objectives include comprehensive safety assessment (CTCAE v5.0 graded AEs) and clinical activity measures (PFS/OS) to characterize HDP-101's therapeutic profile, with all endpoints monitored throughout the 1-year study duration.
|
||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.01 nM
|
|||
| Method Description |
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
|
||||
| In Vitro Model | Plasma cell myeloma | U266B1 cells | CVCL_0566 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.04 nM
|
|||
| Method Description |
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
|
||||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.16 nM
|
|||
| Method Description |
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
|
||||
| In Vitro Model | Plasma cell myeloma | MM1.S cells | CVCL_8792 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.18 nM
|
|||
| Method Description |
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
|
||||
| In Vitro Model | Plasma cell myeloma | INA-6 cells | CVCL_5209 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.3 nM
|
|||
| Method Description |
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
|
||||
| In Vitro Model | Plasma cell myeloma | LP-1 cells | CVCL_0012 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.34 nM
|
|||
| Method Description |
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
|
||||
| In Vitro Model | Multiple myeloma | SK-MM-1 cells | CVCL_A478 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
4.83 nM
|
|||
| Method Description |
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
|
||||
| In Vitro Model | Plasma cell myeloma | L-363 cells | CVCL_1357 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
34.2 nM
|
|||
| Method Description |
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
|
||||
| In Vitro Model | Plasma cell myeloma | OPM-2 cells | CVCL_1625 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
142 nM
|
|||
| Method Description |
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
|
||||
| In Vitro Model | Plasma cell myeloma | RPMI-8226 cells | CVCL_0014 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 1000 nM | |||
| Method Description |
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
|
||||
| In Vitro Model | Osteosarcoma | U2OS cells | CVCL_0042 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 1000 nM | |||
| Method Description |
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
|
||||
| In Vitro Model | Normal | HS-5 cells | CVCL_3720 | ||
References